Scarica l'app Stockscreener
72.57
0.07%
0.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$72.52
Aprire:
$72.59
Volume 24 ore:
2.65M
Relative Volume:
0.97
Capitalizzazione di mercato:
$11.38B
Reddito:
$1.21B
Utile/perdita netta:
$109.52M
Rapporto P/E:
104.24
EPS:
0.6962
Flusso di cassa netto:
$269.60M
1 W Prestazione:
+0.15%
1M Prestazione:
+0.33%
6M Prestazione:
+26.52%
1 anno Prestazione:
+17.81%
Intervallo 1D:
$72.45
$72.59
Intervallo di 1 settimana:
$72.44
$72.61
Portata 52W:
$43.20
$72.69
Bio Techne Corp Stock (TECH) Company Profile
Nome
Bio Techne Corp
Settore
Industria
Telefono
612-379-8854
Indirizzo
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
72.57 | 11.38B | 1.21B | 109.52M | 269.60M | 0.6962 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-08-13 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-06-11 | Iniziato | Piper Sandler | Neutral |
| 2026-05-15 | Ripresa | RBC Capital Mkts | Outperform |
| 2025-09-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-08-21 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-07-22 | Ripresa | Stephens | Overweight |
| 2025-07-09 | Iniziato | TD Cowen | Buy |
| 2025-05-30 | Iniziato | Wells Fargo | Overweight |
| 2025-04-09 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | Iniziato | Evercore ISI | Outperform |
| 2025-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-08 | Iniziato | Scotiabank | Sector Outperform |
| 2024-02-02 | Downgrade | Stifel | Buy → Hold |
| 2023-12-07 | Iniziato | UBS | Buy |
| 2023-08-28 | Iniziato | William Blair | Outperform |
| 2023-01-10 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-12-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-04-25 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | Aggiornamento | Stifel | Hold → Buy |
| 2021-01-25 | Reiterato | The Benchmark Company | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-07-15 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | Downgrade | Stifel | Buy → Hold |
| 2020-05-14 | Iniziato | The Benchmark Company | Buy |
| 2020-01-08 | Ripresa | Stephens | Overweight |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Neutral |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-07-02 | Aggiornamento | Janney | Neutral → Buy |
| 2019-01-14 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | Downgrade | Craig Hallum | Buy → Hold |
| 2018-10-17 | Iniziato | Goldman | Neutral |
| 2018-06-15 | Iniziato | Argus | Buy |
| 2017-07-13 | Iniziato | Wells Fargo | Market Perform |
| 2017-02-09 | Iniziato | Citigroup | Buy |
| 2017-01-18 | Iniziato | Deutsche Bank | Buy |
| 2016-11-10 | Ripresa | Leerink Partners | Outperform |
| 2015-01-21 | Reiterato | Robert W. Baird | Outperform |
| 2013-09-20 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
Mostra tutto
Bio Techne Corp Borsa (TECH) Ultime notizie
Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development - Investing News Network
Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development - Yahoo Finance
Bio-Techne Company Profile & Introduction - Moomoo
INCY or TECH: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Robert V Baumgartner Exercises Options, Realizes $754KBio-Techne (NASDAQ:TECH) - Benzinga
Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package - Yahoo Finance
Bio-Techne (TECH) director exercises options and delivers or withholds 5,559 shares for costs or taxes. - Stock Titan
Bio-Techne shareholders approve $11.3 billion merger with German Merck - AKM.RU
What Does Shareholder Approval Mean for Bio-Techne's (NASDAQ:TECH) Merck KGaA Deal? - Kalkine Media
Is Bio-Techne Stock Outperforming the Nasdaq? - finance.yahoo.com
Is Bio-Techne Stock Outperforming the Nasdaq? - barchart.com
Form 8K Bio-Techne Corp For: 23 September By Investing.com - Investing.com Canada
Form 8K Bio-Techne Corp For: 23 September - Investing.com India
Merck KGaA's USD 11.3b Bio-Techne acquisition clears final shareholder approval hurdle - AllSci
Bio-Techne (TECH) Opens Düsseldorf Hub As Fair Value Questions Come Into Focus - simplywall.st
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany - Investing News Network
Bio-Techne shareholders approve Merck KGaA acquisition - Investing.com
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany - PR Newswire
Bio-Techne Opens New Customer Experience Center in Germany - marketscreener.com
Bio-Techne Opens New Customer Experience Center in Germany - finance.yahoo.com
Bio-Techne opens customer experience center in Düsseldorf - Investing.com
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration - marketscreener.com
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration - Yahoo Finance
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration - Investing News Network
Bio-Techne Corp (TECH) Investor Outlook: Navigating Market Dynamics with a Focus on Growth Potential - DirectorsTalk Interviews
Why Is Techne (TECH) Down 0.1% Since Last Earnings Report? - Zacks Investment Research
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger – AUUD, TECH, CZR and CBAN - GlobeNewswire Inc.
Research Use Recombinant Protein Market Report Now Available — Forecasts Market Growth from $1.11B (2026) to $1.55B by 2031, Profiling Thermo Fisher, Bio-Techne, Merck KGaA, Danaher, Revvity, and Others - Yahoo Finance UK
Bio-Techne Corp (TECH) Stock Analysis: Navigating Its Current Valuation and Growth Potential - DirectorsTalk Interviews
Bio-Techne Corp (NASDAQ: TECH) Share Price, TECH Stock News, TECH Share Price & Updates - Kalkine
Ademi LLP investigates Bio-Techne sale to Merck KGaA - scanx.trade
Global Multiplex Assays Market 2026 Edition Consumables Dominate Multiplex Assays with 68% Market Share - GlobeNewswire Inc.
Bio-Techne (TECH), What Is Behind The Latest Attention? - simplywall.st
TECH: Bio-Techne Corp Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals - marketscreener.com
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals - Stock Titan
Bio-Techne Corp (TECH) Stock Analysis: Evaluating the Balance Between Growth Potential and Current Valuation - DirectorsTalk Interviews
Winners And Losers Of Q2: Bio-Techne (NASDAQ:TECH) Vs The Rest Of The Research Tools & Consumables Stocks - Yahoo Finance
Legal & General buys $19.51M stake in Bio-Techne - Dealroom
Bio-Techne Corp (TECH) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Bio-Techne To Be Acquired by Merck KGaA - Morningstar
BIO-TECHNE Corp FY 2026: Revenue $1.22B, EPS $1.16— 10-K Summary - TradingView
Bio-Techne draws fresh institutional cash as revenue climbs to $321M - app.dealroom.co
Bio-Techne Gives FTC More Time On $11.3B Merck Deal - Law360
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation? - TradingView
Bio-Techne (Nasdaq: TECH) investors to vote on Merck cash takeover - Stock Titan
Bio-Techne (NASDAQ: TECH) GC gets new RSU grants, no stock sales - Stock Titan
Bio-Techne (NASDAQ: TECH) grants CFO 22,438 and 36,459 RSUs - Stock Titan
Bio-Techne (TECH) director granted 1,381 RSUs vesting 2027-29 - Stock Titan
Bio-Techne (TECH) insider updates stock holdings - Stock Titan
Bio Techne Corp Azioni (TECH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Bio Techne Corp Azioni (TECH) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BAUMGARTNER ROBERT V | Director |
Sep 22 '26 |
Option Exercise |
0.00 |
15,940 |
0 |
62,443 |
| Bohnen Shane | SVP - General Counsel |
Aug 15 '26 |
Option Exercise |
0.00 |
4,350 |
0 |
11,703 |
| Crouse Steven C. | President - Diag & Spatial Bi |
Aug 15 '26 |
Option Exercise |
0.00 |
5,423 |
0 |
12,184 |
| Herr Amy E. | Director |
Aug 15 '26 |
Option Exercise |
0.00 |
589 |
0 |
789 |
| Kelderman Kim | Chief Executive Officer |
Aug 15 '26 |
Option Exercise |
0.00 |
21,470 |
0 |
93,583 |
| Hippel James | CFO |
Aug 15 '26 |
Option Exercise |
0.00 |
9,779 |
0 |
174,493 |
| Geist William | PRESIDENT, PROTEIN SCIENCES |
Aug 15 '26 |
Option Exercise |
0.00 |
6,416 |
0 |
26,919 |
| Hippel James | CFO |
Jul 29 '26 |
Option Exercise |
47.60 |
62,068 |
2,954,437 |
215,738 |
| Kelderman Kim | Chief Executive Officer |
Jul 28 '26 |
Option Exercise |
47.60 |
35,000 |
1,666,000 |
100,799 |
| Bohnen Shane | SVP - General Counsel |
Jul 23 '26 |
Option Exercise |
47.60 |
448 |
21,325 |
7,697 |
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):